• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • MANUFACTURERS
  • HEADHUNTERS
  • PRODUCT SECTIONS
  • COMPANIES

SPINEMarketGroup

Spine Industry News

  • HOME
  • 2025
  • 2024
  • BROCHURES
  • ARTICLES
  • VIDEOS

DirectSync Surgical receives Breakthrough Device Designation from FDA for its Patient-Powered Smart Implants

May 2, 2023 By SPINEMarketGroup

LAWRENCE, Kan., May 02, 2023 (GLOBE NEWSWIRE) — DirectSync Surgical, a medical device company dedicated to improving the lives of patients who suffer from spine and orthopedic diseases, has announced that its patient-powered smart spinal fusion device has received Breakthrough Device Designation by the US Food and Drug Administration.

“An all-in-one interbody fusion device that has a therapeutic aspect as well as a diagnostic tool to allow me to know when and if fusion is taking place has the potential to revolutionize my practice.”

“Today’s announcement is an important milestone for DirectSync Surgical and highlights the urgent need to improve spinal fusion outcomes while empowering physicians and their patients with a more robust post-operative continuum of care,”

“Obtaining breakthrough designation from FDA indicates our technology will significantly improve the standard of care and provide more timely access to patients and health care providers.”

“An all-in-one interbody fusion device that has a therapeutic aspect as well as a diagnostic tool to allow me to know when and if fusion is taking place has the potential to revolutionize my practice.”

“Today’s announcement is an important milestone for DirectSync Surgical and highlights the urgent need to improve spinal fusion outcomes while empowering physicians and their patients with a more robust post-operative continuum of care,”

“Obtaining breakthrough designation from FDA indicates our technology will significantly improve the standard of care and provide more timely access to patients and health care providers.”

“An all-in-one interbody fusion device that has a therapeutic aspect as well as a diagnostic tool to allow me to know when and if fusion is taking place has the potential to revolutionize my practice.”

To meet the designation criteria, FDA has reviewed the company’s preliminary data and determined that the DirectSync Surgical interbody device may provide a more effective treatment of an irreversibly debilitating condition than the current standard of care. The product delivers localized electrical stimulation and provides post-operative diagnostics to achieve fusion more effectively for patients indicated for spinal fusion. FDA’s Breakthrough Devices Program is intended to expedite development and review of medical devices that are designed to treat serious or life-threatening diseases.

“Today’s announcement is an important milestone for DirectSync Surgical and highlights the urgent need to improve spinal fusion outcomes while empowering physicians and their patients with a more robust post-operative continuum of care,” said Zygmunt Porada, CEO of DirectSync Surgical. “Obtaining breakthrough designation from FDA indicates our technology will significantly improve the standard of care and provide more timely access to patients and health care providers.”

Dr. Paul Arnold, Chairman of Neurosurgery at Carle Foundation Hospital in Illinois and Co-Founder of DirectSync Surgical said: “An all-in-one interbody fusion device that has a therapeutic aspect as well as a diagnostic tool to allow me to know when and if fusion is taking place has the potential to revolutionize my practice.”

DirectSync Surgical has successfully completed a NIH Phase II SBIR grant that supported a comparative randomized pre-clinical bone growth assessment and is currently completing a second NIH Phase I SBIR grant to integrate diagnostics to monitor key healing metrics. DirectSync Surgical is raising a Seed Round to accelerate efforts to initiate first-in-human studies.

Investment Inquiries:
Zyg Porada
phone: 443-641-6227
e-mail: [email protected]

About DirectSync Surgical 

DirectSync Surgical is developing the first-ever patient-powered smart implant which reduces heavy reliance on constantly powering and monitoring the device remotely. While the patient goes about their daily life, the DirectSync interbody is hard at work providing targeted mechanically synced electrical stimulation for enhanced bone healing and post-operative data collection to inform and optimize the treatment regimen between the physician and their patient. https://www.directsyncsurg.com

(Visited 111 times, 23 visits today)

Filed Under: NEWS Tagged With: 2023, NEWS

Reader Interactions

Trackbacks

  1. (Updated 2023): Smart Implant Companies to Know..! - SPINEMarketGroup says:
    May 3, 2023 at 8:26 am

    […] The global market for smart implants is estimated to have a market value of more than $22.2 billion by 2032. Soon, many companies will create revolutionary implants with better outcomes and cost savings. A few weeks ago we talked about the company Intelligent Implants as an innovative company in the smart cages segment. Today we update this article by adding the company DirectSync Surgical that recently received Breakthrough Device Designation from FDA for its Patient-Powered Smart Implants. […]

Primary Sidebar

PLATINUM SPONSORS

GOLD SPONSORS

MOST POPULAR POSTS

  • BROCHURES
  • Just Reflective, Not Disappointed: Globus Medical’s…
  • (UPDATED 2025): 6 Artificial Cervical Discs You’ll…
  • What’s Happening with Globus Medical? Why Has the…
  • (UPDATED 2024): +8 Lumbar Artificial Discs to Know…
  • Stryker’s Spine Business Sale: A Smart Move or a…
  • Why Didn’t Globus Medical’s Stock Rise After…
  • Globus Medical extends versatility of Advanced…
  • Globus Medical to Execute $500 Million Share Buyback…
  • Dispute Over Spinal Implant Royalties Between…
  • M6 Discontinued: What Are the Alternatives for a…
  • Eminent Spine’s 3D Printed Titanium Pedicle Screw…
  • Orthofix Discontinues M6-C™ and M6-L™ Artificial…
  • Stryker’s Spine Exit: What It Means for…
  • Alphatec Today: Where It Stands and Where It’s Heading?
  • (Updated!) 15 Expandable PLIF Cages to Know…!
  • (UPDATED 2024): +108 Stand-Alone Cervical Cages to Know..!
  • Globus Medical Reports First Quarter 2025 Results
  • What Are the Strategic Reasons Behind Globus…
  • Viscogliosi Brothers Completes Acquisition of U.S.…
  • LAST 10 VIDEOS PUBLISHED

    1. Biedermann Motech: MOSS 100 (Short)
    2. POWEHI MEDICAL AG: KUDOS™ Modular
    3. POWEHI MEDICAL AG: TANTO® Screw
    4. Syntropiq: Taurus TLIF (Short)
    5. LEM Surgical: Dynamis Surgical Robot
    6. Aegis Spine:PathLoc-TA
    7. NGMedical: MOVE®-C Artificial Disc
    8. B.Braun Aesculap: Ennovate® Cervical MIS
    9. Spineart: PERLA® TL Deformity Solutions
    10. NGMedical: MOVE®-C

    Recent Comments

    • Peter on A New Player in Spinal Care, POWEHI Medical!
    • Sandy on Just Reflective, Not Disappointed: Globus Medical’s Bittersweet Q1 2025
    • SPINEMarketGroup on M6 Discontinued: What Are the Alternatives for a Cervical Artificial Disc?
    • Sergio López-Fombona on M6 Discontinued: What Are the Alternatives for a Cervical Artificial Disc?
    • Drew on Has Globus Already Surpassed Medtronic in the Spine Market? Can J&J Find Its Way Back to the Top?
    • Ahmed Hassan El-Naggary on Has Globus Already Surpassed Medtronic in the Spine Market? Can J&J Find Its Way Back to the Top?
    • Email
    • Twitter
    • YouTube

    Subscribe to Our Newsletter!

    Check your inbox or spam folder to confirm your subscription.

    Footer

    • Email
    • Twitter
    • YouTube

    Contact us:

    [email protected] [email protected]

    PRIVATE POLICY

    • Legal Advice
    • Embed Link
    • VIDEOS

    Copyright © 2025 · SPINEMarketGroup

    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    View preferences
    {title} {title} {title}